Phase 2 N=34 Chamomile for Chronic Primary Insomnia
Primary Insomnia · Chronic Insomnia
Primary: Change From Baseline of Chamomile Extract on Measures of Sleep at Day 28. — 83.3; 77.5 percentage of time asleep — p=0.21
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 Treatment of Insomnia Secondary to Chronic Pain
Insomnia · Pain
Primary: Insomnia Severity — 6.0; 12.8; 4.4; 13.0 units on a scale — p=0.010
N/A N=211 Sequenced Therapies for Comorbid and Primary Insomnias
Insomnia Comorbid to Psychiatric Disorder · Primary Insomnia
Primary: Percent of Participants Who Met Remission as Measured by the Insomnia Severity Index — 40.00; 34.94; 37.04; 48.15 percent remitted
Phase 3 N=30 Mindfulness Versus Pharmacotherapy for Chronic Insomnia: A Pilot Study
Chronic Insomnia · Primary Insomnia
Primary: Pittsburgh Sleep Quality Index (PSQI) — 7.7; 9.2; 7.0; 8.2 units on a scale
N/A N=28 The Psychoneuroimmunology of Insomnia
Primary Insomnia
Primary: Positive Antibody Response — 7; 7 participants
N/A N=30 Chronic Insomnia and CSF Markers of Dementia
Insomnia Chronic
Primary: CSF Markers Related to Dementia — 4332.1; 4824.0; 393.2; 419.4 picograms per milliliter
N/A N=189 Insomnia Self-Management in Heart Failure
Cardiac Failure · Heart Failure · Congestive Heart Failure
Primary: Change in Insomnia Severity — -6.60; -3.46 score on a scale — p=0.0002
Phase 2 N=118 Internet-based Treatment for Chronic Insomnia
Insomnia · Insomnia Disorder
Primary: Sleep Quality — 1.77; 2.18 0-4 scale of sleep quality
N/A N=28 Hyper-Arousal in Chronic Primary Insomnia
Chronic Insomnia
Primary: Sympathetic Baroreflex Sensitivity (BRS) Unit — -2.1; -4.3 bursts per 100 heart beats per mm Hg
N/A N=188 Sleep Without Insomnia or The Use of Chronic Hypnotics
Sleep Initiation and Maintenance Disorders
Primary: Rates of Hypnotic Discontinuation — 64; 52 Participants — p=.039
Phase 4 N=115 Partial Reinforcement II: Three Approaches to Maintenance Therapy for Chronic Insomnia
Insomnia · Insomnia Chronic
Primary: Treatment Response (Phase 1) — 94 Participants
Phase 3 N=707 Almorexant (ACT 078573) in Adult Subjects With Chronic Primary Insomnia
Primary Insomnia
Primary: Change From Baseline to Day 1&2 in Wake After Sleep Onset (WASO) — 85.0; 86.6; 92.3; 76.5 minutes — p=<0.0001
N/A N=154 Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes
Menopause
Primary: Diary Based Sleepiness — 5.01; 5.13; 4.87; 4.72 score on a scale
Phase 4 N=58 Study of the Insomnia in Patients With Low Back Pain
Primary Insomnia
Primary: Mean Subjective Sleep Diary Derived Total Sleep Time (TST) — 316.96; 380.45; 403.47; 375.56 Minutes
N/A N=110 Non-Pharmacological Treatments for Insomnia in Chronic Traumatic Brain Injury
Insomnia · Traumatic Brain Injury
Primary: Insomnia Severity Index (ISI) — -9.7; -4.72 Units on a scale
N/A N=149 Insomnia Treatment for Women Veterans
Insomnia
Primary: Number of Participants Completing 5 Behavioral Treatment Sessions — 63; 70 Participants — p==.120
Phase 2 N=42 Effectiveness of BBT-I and Zopiclone for Chronic Insomnia
Insomnia Chronic
Primary: Insomnia Severity Index — 18.6; 18.9; 13.1; 14.0 units on a scale
Phase 3 N=460 A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)
Sleep Initiation and Maintenance Disorders · Mental Disorders · Dyssomnias
Primary: Change From Baseline in Total Sleep Time (TST) - 6-Month Treatment Period — 65.9; 19.3 minutes — p=<0.0001
Phase 4 N=388 A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia
Insomnia
Primary: Mean Change From Baseline in Subject-Reported Total Sleep Time (TST) Averaged Over the 12 Week Double Blind Study Period. — 33.18; 63.24 minutes — p=<0.0001
Phase 4 N=79 Treatment of Insomnia in Migraineurs
Insomnia · Migraine
Primary: Total Sleep Time — 5.4; 5.5; 6.3; 6.1 hours — p=0.33
Phase 3 N=126 Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
Insomnia · End Stage Renal Disease
Primary: Insomnia Severity Index (ISI) Short-term — 12.47; 11.97; 13.05 score on a scale — p=0.6761
N/A N=48 A Cognitive-Behaviour Therapy (CBT) Self-Management Approach for Insomnia in Chronic Pain: A Randomized Control Trial
Insomnia · Chronic Pain
Primary: Insomnia Severity Index (ISI) — 19.84; 16.04 units on a scale
Phase 2 N=112 Almorexant (ACT-078573) in Elderly Subjects With Chronic Primary Insomnia
Chronic Primary Insomnia
Primary: Mean Wake Time After Sleep Onset (WASO) — 109.1; 98.7; 90.0; 77.7 minutes — p=0.0018
N/A N=87 Telemedicine Management of Chronic Insomnia
Sleep Initiation and Maintenance Disorders · Post-Traumatic Stress Disorders
Primary: Change From Baseline in Insomnia Severity Index Score — 6.68; 5.13 units on a scale — p=0.138
N/A N=45 A High Density EEG Comparison of Sleep Patterns in Insomnia
Primary Insomnia
Primary: EEG Power During Sleep — 1.40; 1.17 μV^2/Hz — p=0.2791
N/A N=24 Study of Trazodone & Cognitive Behavioral Therapy to Treat Insomnia
Insomnia
Primary: Change in Objective Polysomnography Sleep Duration From Baseline to Post Treatment (3 Months) — 28.95; 38.91 minutes
N/A N=245 The RESTING Insomnia Study: Randomized Controlled Study on Effectiveness of Stepped-Care Sleep Therapy
Insomnia
Primary: Insomnia Severity Index (ISI) — 15.9; 15.4; 12.7; 11.6 score on a scale — p=0.001
N/A N=100 Prescription Digital Therapeutic for the Treatment of Insomnia
Insomnia Chronic
Primary: Change in Insomnia Severity
Phase 4 N=155 CBT-I or Zolpidem/Trazodone for Insomnia
Chronic Insomnia
Primary: Change in Insomnia Symptom Severity — -8.05; -7.82; -10.19 change score on a scale
Phase 2 N=643 An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
Primary Insomnia · Secondary Insomnia
Primary: Change From Baseline in Average Nightly Total Sleep Time at Week 4 (Week 2 of Period B) Endpoint — 30.16; 37.33; 50.63; 22.79 minutes